Form D · Biotechnology
AbCellera Biologics Inc.
Vancouver, A1 · CIK 0001703057
Offering snapshot reported May 27, 2020 · SEC filing
- Reported sold
- $74.5M Offering amount: $74.5M
- Investors reported
- 14 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Mar 23, 2020 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| May 27, 2020 | Initial | $74,500,235 | No comparison | 14 | SEC filing |
| Aug 10, 2018 | Initial | $7,702,383 | No comparison | 1 | SEC filing |
| Mar 19, 2018 | Initial | $50,000 | No comparison | 1 | SEC filing |
| Apr 6, 2017 | Initial | $817,878 | No comparison | 24 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-367729
Source: Form D, filed May 27, 2020. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Andrew Booth | Executive |
| John Hamer | Director |
| Carl Hansen | Director, Executive |
| Michael Hayden | Director |
| Doug Janzen | Director, Executive |
| Veronique Lecault | Director, Executive |
| Stimart Tryn | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
2215 Yukon Street
Vancouver, A1, V5Y 0A1
Vancouver, A1, V5Y 0A1